Small recurrent skin nodules decreased in size in a third patient treated with large doses of mannitol busulphan. One patient obtained relief of severe pain due to involvement of the brachial plexus, but no objective evidence of improvement was found. She died of bronchitis four weeks after treatment started, when her leucocytes, which had fallen to 450/c.mm., had recovered. Discussion Improvement and objective temporary remission of disseminated breast carcinoma has been obtained by the use of mannitol busulphan. Two of five patients given smaller doses obtained some benefit, and three, possibly four, of six patients who were given larger doses obtained objective improvement. It is probable that the degree of benefit depends on the amount of drug administered, and unless enough is given to damage the bone-marrow the effect on the growth is likely to be negligible.
Several reports of the treatment of disseminated carcinoma of the breast with alkylating agents have appeared. In most series between one-third and onefifth of the patients treated have responded (Moore, 1958; Gurling, 1959) . It has been suggested that patients who respond well to other forms of treatment may have a better chance of benefiting from chemotherapy (Gurling, 1959) . In all but one of the patients treated in this series response to mannitol busulphan has been similar to that which followed previous hypophysectomy. Hypophysectomy, however, was undertaken in some as a final hormonal resort, and response to chemotherapy is not similar in all cases to the response to hormonal therapy prior to hypophysectomy. The one patient (Case 3) on whom pituitary ablation was performed after treatment with mannitol busulphan obtained a better response to pituitary ablation than to the chemotherapy.
Persistent treatment with an alkylating agent may result in destruction of slightly more tumour cells in the marrow than bone-marrow cells, with a resulting small advantage to the patient.
Regression of disseminated carcinoma can be produced using mannitol busulphan, but it is difficult to say from such a small series whether this drug offers any advantage over other alkylating agents. No such advantage has become apparent as yet. It is possible that a small advantage is gained by treating patients to the limit of toxicity compared with the results obtained using a less drastic dosage schedule. This would suggest that, as with other similar agents, the effective dosage remains uncomfortably near to the lethal dosage, and close supervision of patients undergoing such therapy, possible only within a hospital, is essential. Anti-cancer agents in use at the present time are either cytotoxic or hormonal, the former including both the alkylating agents and the antimetabolites. This communication is concerned only with the alkylating agents. To use these effectively some method is required to protect the host cells from their effect, particularly on such tissues as bone-marrow and alimentary tract.
Summary
From this basic requirement has grown the concept of isolated regional perfusion, which is an attempt to isolate a tumour in its own vascular bed from the remainder of the body's circulatory system. By this method the isolated tumour-bearing vascular territory is perfused with blood into which can be introduced the appropriate cytotoxic agent in such a manner as to maintain an effective concentration for a given period of time.
Continuous regional intra-arterial infusion -first described by Klopp-is a simpler procedure with a different set of indications. This method is not considered here.
Literature
The first attempt to attain a high concentration of cytotoxic agent in a tumour was made by Klopp et al. (1950) after observing the local effects of an accidental injection of HN2 into the brachial artery.
The use of an extracorporeal pump oxygenator in isolated regional perfusion was reported by Ryan et al. (1957) . This was soon followed by reports from American workers giving results of their experiences Reemtsma et al., 1959; Creech, Krementz et al., 1959) .
Using dogs and perfusing the hind limbs with melphalan (phenylalanine mustard), Ryan et al. (1957) showed that 2 mg./kg. body weight was well tolerated, but doses above 3 mg./kg. were lethal.
Creech, Ryan, a'nd reported that they had perfused 41 patients with malignant neoplasms in various sites, including eight with malignant melanoma of the lower extremity; all except one were perfused with melphalan, 2 mg./kg. The exception, in whom isolation of the perfusion area was incomplete, was perfused via the abdominal aorta with 3 mg. of melphalan per kg. body weight, and died on the fifteenth post-operative day as a result of severe marrow depression, thus supporting the experimental findings of Ryan et al. (1957) , referred to above. Follow-up of the remaining seven patients one year before publication of the results showed all seven to be alive and their disease controlled.
In a further communication Creech, Krementz, Ryan, Reemtsma, and Wimblad (1959) Creech concluded that while some cancers could be controlled by perfusion there were great and unpredictable variations in response even when tumours of the same histological type were treated. This was also the experience of Krementz et al. (1959) . Longmore (1960) reported his results of perfusion in three cases of cerebral neoplasm, two of sarcoma, and one of melanoma of a limb. He obtained no evidence of improvement in any patient, and concluded that the complications he encountered probably outweighed the usefulness of the procedure. It is possible that Longmore's results were due to the use of the ester of melphalan-which we now know to be too toxic for use in the same dose range as the salts of melphalan, and also to his use of the high perfusion temperature of 430 C., which we have, so far, found to be unnecessary. Abel (1960) , however, after his tour of America was able to give a more encouraging picture. Other series have been reported by Stehlin et al. (1960) and by Irvine and Noon (1961) .
Present Investigation We have confined our experience to the alkylating agent known as melphalan (phenylalanine mustard; P.A.M.; p-di(2-chloroethyl)aminophenylalanine) first synthesized by Bergel and Stock (1953) and to mustine (nitrogen mustard; HN2; /3-dichloroethylmethylamine hydrochloride). These compounds are sometimes referred to as radiomimetic, and their duration of action is assessed in half-lives; that of melphalan being two hours in blood at 370 C., while mustine is more rapid in its reaction, with a half-life of 12 minutes under the same conditions.
In addition to the suitable half-life of melphalan, there is a further theoretical reason for its use in perfusion of malignant melanomata. It is believed that as phenylalanine is an essential requirement in the production of melanin by the cell, melphalan, which is phenylalanine mustard, will be taken up preferentially by those cells actively engaged in the production of the pigment, and where these are malignant some degree of specificity of action may result. Even when this is not fully achieved it remains a useful general cytotoxic agent. We have found it generally convenient to use 100 mg. where leakage from the perfusion circuit is negligible, or 70 mg. where the leak is 20% or more. The drug is administered by its addition to the reservoir or the perfusion circuit at 10-minute intervals.
Toxic effects are both local and general. The local effects, resulting from an excessive concentration in the perfusate, lead to early changes in the perfused area and include vascular spasm, oedema of tissues, erythema, and later vesiculation of the skin. Arterial spasm and oedema can be treated by papaverine applied around the major vessels at operation. Post-operatively, the limb is cooled by a fan and ice-bags. 'Hydrocortisone 100 mg. intravenously is used when local oedema is causing anxiety.
In only one patient were local changes severe, ultimately necessitating amputation of the leg. This was the only case for which the ester of melphalan was used.
The general effects are those produced by any alkylating agent, but where isolation is good they should not occur. If, however, leakage is considerable, there may be vomiting in the first 24 hours. When bone-marrow depression occurs it usually reaches its maximum by the twelfth day. We no longer take marrow from the patient prior to perfusion for replacement post-operatively, as with good leakage control it is no longer necessary, and where leakage is appreciable the dose of cytotoxic agent is reduced accordingly. Should bone-marrow depression occur and the total leucocyte count fall to 1,500 c.mm. then antibiotics should be given prophylactically.
Methods
In the main the methods used have been those introduced by Creech et al. (1958) . Our methods in the management of regional perfusion as well as our choice and dosage of drugs have been greatly influenced by work carried out on animals and reported elsewhere (Boyland et al., 1961 but rejected. After the perfusion the first and dramatic change was the complete disappearance of pain; 48 hours later the lesions underwent a change. A small area of purulent necrosis developed around each nodule, which began to slough away, and after three weeks the area resembled a gravitational ulcer. This required a further five months to heal (Figs. 2 and 3 ). Eighteen months after perfusion the patient remained well and symptom-free. The nodules higher up the leg and situated more deeply in the subcutaneous tissues have also slowly regressed. Case 6.-This patient, a married woman aged 38, had had malignant melanoma of the left thigh removed a year previously followed by a block dissection of the groin nodes. Six months later a crop of recurrent nodules appeared in the upper thigh. Regional perfusion was performed. A month later the first sign of regression in the nodules was noted, and after a further three months this slow regression was continuing. This delayed reaction has also been noted in another case.
Case 15.-A married woman aged 54 had an advanced, painful, and inoperable carcinoma of the rectum (a colostomy had been made nine months previously). She was receiving heavy sedation for her pain and a pelvic perfusion was therefore performed. Immediately after the perfusion she commented on the relief from pain and required only an occasional drug for sedation. In consequence she was mentally more alert and her general condition improved. She died four months later, but during this time the pain did not recur.
Complications already present; however, the attempt failed. The leg became more oedematous and erythema progressed to gangrene within a few days. In one other case a small patch of gangrene occurred on the heel owing to a combination of stasis, pressure, and the drug.
Bone-marrow depression is not a serious hazard of the treatment, although it has occurred. When perfusing a limb such as a leg through the iliac vessels it is now expected that the drug leakage will be under 5%. In pelvic perfusion it has proved a major complication, as the leak in our hands has always been high. The depression reaches its maximum on about the twelfth day, the white-cell count falling to under l,000/c.mm. Spontaneous recovery has always taken place, but antibiotic cover is given during this phase of leucopenia. Bone-marrow aspiration prior to perfusion and intravenous replacement 12 hours afterwards has undoubtedly aided the phase of recovery; but this in itself has its own complications, because aspirating 300-400 ml. of bone-marrow is a lengthy procedure and causes a fall of blood-pressure, which is undesirable in a patient about to undergo an operation.
The effect of the alkylating agents on some tumour tissues is undoubtedly dramatic. The most satisfying reponse of a tumour to regional perfusion is the " early reaction." Within 48 hours the lesions are surrounded by a red halo of inflammation followed by a mild purulent reaction with separation of the malignant tissues.
In other cases the reaction is less dramatic, the nodules initially showing the red halo reaction which subsequently subsides and is followed by slow regression of the nodules without necrosis and their eventual replacement by fibrous tissue. This may take weeks to occur. We consider it important to recognize this possibility of late regression so as to avoid unnecessary re-perfusion. For this reason we would not advise re-perfusion in less than three months. An additional risk of re-perfusion is the increased sensitivity of the tumour, such as may occur after heavy irradiation.
When a tumour is situated deep in a body cavity, tumour necrosis produced by cytotoxic agents will bring its own complications. In one pelvic tumour necrosis was induced which finally led to peritonitis and was the eventual cause of death. If a fibrotic reaction is attained then slow regression of the tumour without necrosis can be a satisfactory response. The operation of regional perfusion can be a prolonged and major procedure. Exploration of the site at operation may reveal disease so advanced that isolation of vessels is impossible and the attempt may have to be abandoned. Spread of disease to adjacent and regional lymph nodes calls for the conventional extensive surgical block dissection in addition to perfusion.
At the present time, with the cytotoxic agents available and the limitation of the method, malignant melanoma is the most encouraging lesion to treat.
Summary
The development of isolated regional perfusion as a method of control of malignant disease is reviewed.
Experience in the use of this method with melphalan as the cytotoxic agent used is described. The results of treating 18 patients are recorded. Of 21 perfusions on 18 patients the results are regarded as satisfactory in 15. Relief of pain, when present, is a constant response to perfusion, and can be an important consideration in advising the procedure to be performed.
ADDENDUM.-Since this paper was written one of the satisfactory cases of leg perfusion has required a further perfusion for a recurrence of the lesion. A further patient whose leg was perfused has since died as the result of disseminated disease but without evidence of recurrence in the perfused limb. Two additional patients underwent pelvic perfusion for palliation of intractable pain; in one this was successful.
We acknowledge the fullest co-operation of the surgical staff of the Royal Marsden Hospital, and the encouragement given by Mr. R. W. Raven. Our grateful thanks are due to Professor W. V. Mayneord and the department of medical physics at the Royal Marsden Hospital for construction of the perfusion apparatus, to the department of medical photography for the photographs, and to Miss Jean Akister (medical artist) for the diagram.
